AURA
Aura Biosciences IncKey Statistics
About Aura Biosciences Inc
Aura Biosciences Inc is an innovative clinical-stage biotechnology company dedicated to revolutionizing cancer treatment via its proprietary virus-like particle (VLP) technology. The company's lead investigational drug, AU-011, aims to selectively target and destroy ocular cancer cells while sparing adjacent healthy tissue, showcasing potential advancements in targeted therapies. With a strong clinical pipeline addressing critical unmet needs in oncology and a seasoned management team, Aura is well-positioned to make a significant impact in the oncology market. The company’s strategic partnerships further enhance its capabilities in driving forward new solutions in cancer treatment, aligning with the growing demand for precision medicine in the evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-111.66M |
| Operating Margin | 0.00% |
| Return on Equity | -73.50% |
| Return on Assets | -40.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.15 |
| Price-to-Book | 3.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $64.20M |
| Float | $37.12M |
| % Insiders | 1.63% |
| % Institutions | 84.52% |
Historical Volatility
Volatility is currently expanding